Drug Trial News

RSS

Donor-derived dendritic cells teach the immune system to accept new livers

UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.

17 Apr 2026

Concerns rise over breast cancer risk and gender-based efficacy of Ocrevus

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of MS thought to affect around 15 % of patients.

17 Apr 2026

Researchers prove magnetic seizures are comparable to ECT in clinical response

A landmark international clinical trial led by researchers at the Centre for Addiction and Mental Health (CAMH) and University of California San Diego School of Medicine, published in The Lancet Psychiatry, has found that magnetic seizure therapy (MST) is as effective as electroconvulsive therapy (ECT)-the current gold-standard treatment for severe, treatment-resistant depression-with significantly fewer cognitive side effects. The study is the first large-scale, randomized clinical trial to directly compare MST with ECT, marking an important step toward a new treatment option for patients.

16 Apr 2026

Dutch study shows off-label targeted therapies benefit more cancer patients

The largest published prospective evaluation of off-label targeted cancer therapies has shown that more patients could benefit from existing drugs.

15 Apr 2026

Experimental drug shows survival benefit in pancreatic cancer trial

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis.

14 Apr 2026

Clinical trial tests laser therapy for vaginal dryness in breast cancer survivors

The Alliance for Clinical Trials in Oncology is now enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.

13 Apr 2026

Letrozole monotherapy falls short in ovarian cancer clinical trial

Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non inferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression free survival (PFS) in patients with newly diagnosed stage II-IV low grade serous carcinoma of the ovary or peritoneum.

11 Apr 2026

Mezagitamab shows promise in treating immune thrombocytopenia patients

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet counts in patients with immune thrombocytopenia (ITP), an autoimmune disease characterized by elevated platelet destruction and reduced platelet production that increases bleeding risk and compromises quality of life.

11 Apr 2026

University of Cincinnati launches clinical trial to test new drug for prosthetic joint infections

The University of Cincinnati has enrolled the first patients in a new clinical trial that will test the effectiveness of an investigational drug for prosthetic joint infections (PJI).

10 Apr 2026

Sylvester Comprehensive Cancer Center opens new trial for neuroendocrine tumors

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Apr 2026

New monoclonal antibody shows promise for preventing Lyme disease

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.

8 Apr 2026

Duloxetine fails to prevent nerve damage caused by chemotherapy

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

8 Apr 2026

OYE Therapeutics doses first subject in bridging study of intravenous caffeine formulation

OYE Therapeutics Inc., a clinical-stage biotechnology company developing therapies for perioperative and emergency medicine, announced that the first subject has been dosed in its scientific bridging study evaluating OYE-101.

7 Apr 2026

First participants join clinical study to fast-track dementia research in the UK

The Dementia Trials Accelerator has taken a significant step towards transforming dementia clinical trials in the UK by welcoming its first participants into clinics for simple tests that will ultimately get the right people into clinical trials quicker, speeding up vital research.

7 Apr 2026

COCOON trial protocol halves skin toxicities in lung cancer treatment

A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC."

3 Apr 2026

Gene-edited treatment shows promising outcomes for severe sickle cell disease

New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options.

1 Apr 2026

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.

1 Apr 2026

PRISM ALS: A new global collaboration to expand patient-derived stem cell models and accelerate treatments

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for testing treatments do not currently reflect the diverse nature of the disease - that affects both researchers developing therapies and the people urgently waiting for them.

From ALS Therapy Development Institute (ALS TDI) 1 Apr 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of non-calcified plaque in their coronary arteries after taking the triglyceride-lowering drug olezarsen, in a one-year sub-study presented at the American College of Cardiology's Annual Scientific Session.

30 Mar 2026